Transcatheter Aortic Valve Replacement for Transcatheter Aortic Valve Failure

Overview

About this study

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo TAVR.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • BVF of a TAV (either Medtronic or Edwards) requiring redo TAVR

Exclusion Criteria

  • BVF due solely to paravalvular regurgitation.
  • Active endocarditis
  • Untreated acute valve thrombosis.
  • Life-expectancy less than 1-year.
  • Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable.
  • Participating in another study that may influence the outcome of this study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/11/2024. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mohamad Adnan Alkhouli, M.D., M.B.A.

Contact us for the latest status

Contact information:

Structural Heart Disease Research Coordinators

(507) 255-6133

More information

Publications

Publications are currently not available